Clinical Trials

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB.

The purpose of this study is to investigate if systemic psoriasis medication changes the makeup of lipoproteins (substances made up of fat and protein), cholesterol, and other proteins in the blood.

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at home or the office are both common treatments for psoriasis but it is not known how well they compare to one another.

This study will test if low-dose oral minoxidil has an effect on permanent chemotherapy-induced alopecia (defined as hair loss after the completion of a chemotherapy regimen that persists for over six months). In this study, you will receive the study drug; there is no placebo option. The effectiveness and safety of the treatment will be determined by a range of assessments, including biopsies, images, and subjective evaluation of perceived hair growth.

The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. Another purpose is to find out if guselkumab can cause side effects (unexpected or unwanted reactions from taking a drug).

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience.

Additionally, researchers are interested in:

• Observing how skin condition treatments work and understand side effects caused by these medicines and how these are managed
• Identifying other types of conditions associated with skin disorders
• Collecting patient reported outcomes to better understand the patient perspective and feelings patients have about having a skin condition
• Assessing the impact of Patient Support Programs for individuals with skin conditions and how these programs affect skin condition outcomes
• Creating a “Biorepository Specimen Bank” with blood and saliva samples

Pediatric volunteers with ichthyosis and their parents are needed for a study to better understand the frequency and severity of bullying experienced by children with ichthyosis, and the psychosocial effects of this bullying.

The purpose of this study is to provide use of the gene therapy study drug Beremagene Geperpavec (B-VEC) for participants who have previously completed the parent phase 3 study or for those who were unable to participate in the phase 3 study and would now like to receive treatment with the study drug.

The purpose of this study is to collect characteristic data from patients with atopic dermatitis (AD) or other chronic inflammatory skin disorders (CISDs), such as chronic urticaria, generalized pruritus, prurigo nodularis, pemphigus vulgaris, bullous pemphigoid, mycosis fungoides, cutaneous T cell lymphoma, psoriasis, hidradenitis through an online survey.

The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris.

The purpose of this study is to find out how long ustekinumab stays in and acts in the body. It is investigating how much ustekinumab is present in people's bodies (called a "drug level"). This is measured by blood tests. Another purpose is to find out if ustekinumab can cause side effects, which are unexpected or unwanted reactions from taking a drug. Study participation is a maximum of 16 weeks. No study drug will be provided for this study, only study procedures (blood draw, specific vital signs) will be performed.

The purpose of this study is to determine if individuals with PPD allergies react to synthetic melanin (the pigment that gives your skin its color) or the compounds that comprise it. Most commercial hair dyes contain PPD, a compound that is known to cause allergic reactions. This study aims to investigate the possibility of using synthetic melanin as a hair dye as an alternative.

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.

This study aims to elucidate the burden of atopic dermatitis (AD) in adolescent patients and to look at the impact of dupilumab on that disease burden. The study will measure changes in cognitive and sensory functioning in adolescents with moderate-to-severe AD treated with dupilumab.

The purpose of this study is to evaluate the effectiveness and safety of a new experimental drug named lacutamab (IPH4102).

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.

As the number of available treatments for psoriasis and atopic dermatitis (AD) grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in subjects with AD or psoriasis.

The purpose of this study is to evaluate and compare the efficacy and tolerability of two similar commercially available over the counter acne regimens (Geologie and Proactiv) in individuals with mild to moderate acne vulgaris over a 12-week daily treatment course.